Phillip Angart

Center for Drug Evaluation and Research,

Office of Product Quality,

Office of Biotechnology Products,

Division of Biotechnology Review and Research II,

Center for Drug Evaluation and Research, Office of Product Quality, Office of Biotechnology Products, Division of Biotechnology Review and Research II

U.S. Food and Drug Administration

We use cookies to enhance your experience on our website.

By continuing to use our website or clicking “Continue”, you are agreeing to accept our cookies.

Learn More